Compare CVM & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVM | RAND |
|---|---|---|
| Founded | 1983 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 41.2M |
| IPO Year | 1987 | N/A |
| Metric | CVM | RAND |
|---|---|---|
| Price | $5.29 | $11.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.6K | 5.4K |
| Earning Date | 02-13-2026 | 03-09-2026 |
| Dividend Yield | N/A | ★ 10.32% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,327,287.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $10.56 |
| 52 Week High | $20.41 | $31.89 |
| Indicator | CVM | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 39.97 |
| Support Level | $4.90 | $11.00 |
| Resistance Level | $6.75 | $11.39 |
| Average True Range (ATR) | 0.64 | 0.32 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 21.62 | 12.67 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.